LINK MT MEDICAL GUIDE
Immune Cell & Advanced Medicine
“Advanced” is not a sufficient label. We separate approved care, clinical trials, expanded-access trials, preclinical work and basic research.
Priority areas
Cancer immunology, cell therapy, regenerative medicine, cancer genomics, targeted drugs, new medicines, SaMD and medical AI.
What we verify
Indication, approval status, pivotal evidence, provider, eligibility, cost and visit frequency.
International patients
A drug or trial name does not mean overseas patients are eligible. Pathology, biomarkers and treatment history must be reviewed first.
Principle
Experimental therapy is never presented as established care. Differentiation comes from evidence and a compliant clinical pathway.
Contact
Each item is presented with its evidence level, indication and regulatory status clearly separated.